Aspira Women’s Health (NASDAQ:AWH) Now Covered by Analysts at StockNews.com

Posted by Alanna Baker on Nov 14th, 2024

StockNews.com assumed coverage on shares of Aspira Women’s Health (NASDAQ:AWH – Free Report) in a report released on Wednesday morning. The brokerage issued a hold rating on the stock.

Separately, Alliance Global Partners cut their target price on Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research report on Wednesday, August 14th.

Check Out Our Latest Analysis on AWH

Aspira Women’s Health Trading Down 2.2 %

NASDAQ:AWH opened at $0.82 on Wednesday. The stock has a 50-day moving average price of $0.86 and a 200 day moving average price of $1.44. The stock has a market capitalization of $13.17 million, a P/E ratio of -0.57 and a beta of 1.44. Aspira Women’s Health has a 12-month low of $0.74 and a 12-month high of $5.65.

Aspira Women’s Health (NASDAQ:AWH – Get Free Report) last issued its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.04. The business had revenue of $2.42 million for the quarter, compared to the consensus estimate of $2.60 million. During the same period last year, the business posted ($0.28) EPS. On average, research analysts predict that Aspira Women’s Health will post -1.26 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aspira Women’s Health

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. increased its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH – Free Report) by 88.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 236,396 shares of the company’s stock after purchasing an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned approximately 1.90% of Aspira Women’s Health worth $352,000 as of its most recent SEC filing. 12.19% of the stock is owned by institutional investors and hedge funds.

About Aspira Women’s Health

(Get Free Report)

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.